• Molecular NameEsomeprazole
  • Synonymesomeprazole; Esomeprazole Sodium; Esomperazole
  • Weight345.423
  • Drugbank_IDDB00736
  • ACS_NO119141-88-7
  • Show 3D model
  • LogP (experiment)2.23
  • LogP (predicted, AB/LogP v2.0)2.44
  • pka4
  • LogD (pH=7, predicted)2.43
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-3.95
  • LogSw (predicted, AB/LogsW2.0)0.26
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds5
  • TPSA96.31
  • StatusFDA approved
  • AdministrationOral, IV
  • PharmacologyA proton pump inhibitor (brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium) developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability70.0
  • Protein binding96.0
  • Volume of distribution (VD)0.25 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C19, CYP3A4)
  • Half life0.9 h
  • Excretion80% Renal 20% Faecal
  • Urinary Excretion<1
  • Clerance4.1 ml/min/kg
  • ToxicityBlurred vision, confusion, drowsiness, dry mouthflushingheadache, nausea, rapid heartbeat, sweating
  • LD50 (rat)N/A
  • LD50 (mouse)N/A